Literature DB >> 23390210

A randomised controlled trial of an SMS-based mobile epilepsy education system.

Pei Lin Lua1, Widiasmoro Selamat Neni.   

Abstract

We evaluated an epilepsy education programme based on text messaging (SMS). Epilepsy outpatients from three hospitals in Malaysia were randomised into two groups: intervention and control. Patients in the control group were supplied with printed epilepsy educational material while those in the intervention group also received text messages from the Mobile Epilepsy Educational System (MEES). A total of 136 patients completed the study (mean age 31 years; 91% Malay; 51% with an illness duration of more than 5 years). A between-group analysis showed that the awareness, knowledge and attitudes (AKA) about epilepsy did not significantly differ between the groups at baseline (P > 0.05). The intervention patients reported better AKA levels during follow-up compared to the control patients (P < 0.05). A within-group analysis showed that in intervention patients, there were significant improvements in all AKA domains with larger effect sizes (P < 0.01) while control patients also exhibited significant improvement in most domains except for Awareness but with smaller effect sizes. After controlling for possible confounding variables (age, gender, educational qualification, monthly income and baseline mean for each domain), the intervention group still reported significantly higher AKA than the control group particularly in Awareness (P < 0.001) and Total AKA (P = 0.003). There was also significantly better medication adherence and clinic attendance in the intervention group (P < 0.05). The results suggest that the addition of the MEES to conventional epilepsy education is effective in improving AKA.

Entities:  

Mesh:

Year:  2013        PMID: 23390210     DOI: 10.1177/1357633X12473920

Source DB:  PubMed          Journal:  J Telemed Telecare        ISSN: 1357-633X            Impact factor:   6.184


  9 in total

1.  Text Message Intervention (TEACH) Improves Quality of Life and Patient Activation in Celiac Disease: A Randomized Clinical Trial.

Authors:  Kelly Haas; Andrew Martin; K T Park
Journal:  J Pediatr       Date:  2017-03-23       Impact factor: 4.406

Review 2.  Use of mHealth systems and tools for non-communicable diseases in low- and middle-income countries: a systematic review.

Authors:  David Peiris; Devarsetty Praveen; Claire Johnson; Kishor Mogulluru
Journal:  J Cardiovasc Transl Res       Date:  2014-09-11       Impact factor: 4.132

Review 3.  Epilepsy: behavioural, psychological, and ketogenic diet treatments.

Authors:  Helen Cross
Journal:  BMJ Clin Evid       Date:  2015-07-10

Review 4.  Psychological treatments for people with epilepsy.

Authors:  Rosa Michaelis; Venus Tang; Sarah J Nevitt; Janelle L Wagner; Avani C Modi; William Curt LaFrance; Laura H Goldstein; Milena Gandy; Rebecca Bresnahan; Kette Valente; Kirsten A Donald; Markus Reuber
Journal:  Cochrane Database Syst Rev       Date:  2020-09-07

5.  Health-related quality of life improvement via telemedicine for epilepsy: printed versus SMS-based education intervention.

Authors:  Pei Lin Lua; Widiasmoro Selamat Neni
Journal:  Qual Life Res       Date:  2013-01-18       Impact factor: 4.147

Review 6.  Psychological treatments for people with epilepsy.

Authors:  Rosa Michaelis; Venus Tang; Janelle L Wagner; Avani C Modi; William Curt LaFrance; Laura H Goldstein; Tobias Lundgren; Markus Reuber
Journal:  Cochrane Database Syst Rev       Date:  2017-10-27

7.  mHealth Application Areas and Technology Combinations*. A Comparison of Literature from High and Low/Middle Income Countries.

Authors:  Haitham Abaza; Michael Marschollek
Journal:  Methods Inf Med       Date:  2017-08-08       Impact factor: 2.176

Review 8.  Telemedicine for epilepsy support in resource-poor settings.

Authors:  Victor Patterson
Journal:  Front Public Health       Date:  2014-08-21

9.  Managing Epilepsy by Telemedicine in Resource-Poor Settings.

Authors:  Victor Patterson
Journal:  Front Public Health       Date:  2019-11-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.